Browse > Article
http://dx.doi.org/10.14475/kjhpc.2019.22.2.100

Two Cases of Opioid-Induced Hyperalgesia in Cancer Patients Treated with Opioids for Pain Management  

Hong, Sukchul (Department of Internal Medicine, Kangdong Sacred Heart Hospital)
Kwon, Jung Hye (Department of Internal Medicine, Kangdong Sacred Heart Hospital)
Han, Su Jung (Palliative Care Clinic, Kangdong Sacred Heart Hospital)
Publication Information
Journal of Hospice and Palliative Care / v.22, no.2, 2019 , pp. 100-104 More about this Journal
Abstract
Opioids are important drugs for the management of severe cancer pain without a ceiling effect. However, opioid administration leads to dose-limiting complications including drowsiness, hallucinations, delirium, respiratory depression, cognitive impairment, seizure, myoclonus, and hyperalgesia. Opioid-induced hyperalgesia (OIH) is a paradoxical phenomenon as opioid exposure increases pain sensitivity. Reducing or stopping opioids, opioid rotation, or co-administration of N-methyl-D-aspartate (NMDA) antagonists have been suggested for the management of OIH. In this study, we report two clinical cases of successful management of OIH in cancer pain patients that were treated with opioids.
Keywords
Neoplasms; Pain; Opioid analgesics; Hyperalgesia;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Portenoy RK. Cancer pain. Epidemiology and syndromes. Cancer 1989;63(11 Suppl):2298-307.   DOI
2 Green CR, Hart-Johnson T, Loeffler DR. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer 2011;117:1994-2003.   DOI
3 Chwistek M. Recent advances in understanding and managing cancer pain. F1000Res 2017;6:945.   DOI
4 Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician 2008r;11(2 Suppl):S105-20.
5 Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ. The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharmacol Toxicol 2015;55:55-74.   DOI
6 Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011;14:145-61.
7 Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011;12:601-10.   DOI
8 Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016;65:1-49.   DOI
9 Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin Interv Aging 2008;3:273-8.   DOI
10 Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-50.   DOI
11 Lim KH, Nguyen NN, Qian Y, William JL, Lui DD, Bruera E, Yennurajalingam S. Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care. J Palliat Med. In press 2018.
12 Fallon M, Cherny N. Opioid therapy: optimizing analgesic outcomes. In: Cherny NI, Fallon M, Kassa S, Portenoy RK, Currow D, eds. Oxford textbook of palliative medicine. 5th ed. Oxford:Oxford University Press;2018. p.525-59.
13 Bekhit MH. Opioid-induced hyperalgesia and tolerance. Am J Ther 2010;17:498-510.   DOI
14 Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104:570-87.   DOI
15 Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105-20.
16 Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care 2005;22:291-4.   DOI
17 Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: Cellular and molecular mechanisms. Neuroscience 2016;338:160-82.   DOI
18 Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000;92:465-72.   DOI
19 Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994;14:2301-12.   DOI
20 Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011;14:145-61.
21 Park JH, Lim DH, Kim YH, Ryu KH, Moon DE. Pain managements in pancreatic cancer patient with opioid-induced hyperalgesia : A case report. Anesth Pain Med 2012;7:110-3.
22 Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage 2003;25:302-5.   DOI
23 Romero-Alejo E, Puig MM, Romero A. Antihyperalgesic effects of dexketoprofen and tramadol in a model of postoperative pain in mice - effects on glial cell activation. J Pharm Pharmacol 2016;68:1041-50.   DOI
24 Yanarates O, Dogrul A, Yildirim V, Sahin A, Sizlan A, Seyrek M, et al. Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways. Anesthesiology 2010;112:696-710.   DOI
25 Abreu M, Aguado D, Benito J, Garcia-Fernandez J, Gomez de Segura IA. Tramadol-induced hyperalgesia and its prevention by ketamine in rats: A randomised experimental study. Eur J Anaesthesiol 2015;32:735-41.   DOI